Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "Pathogenic bacterium in gut" does not refer to a single molecule, receptor, or well-defined therapeutic target. Instead, it is an umbrella term encompassing any bacterial species within the gastrointestinal tract that has been associated with disease states or clinical infections. The human gut harbors hundreds of bacterial species—some are beneficial ("probiotic"), many are harmless ("commensal"), while others are considered potentially harmful ("pathogenic") due to their association with infections or outbreaks[1][2][3]. Common examples of **potentially pathogenic gut bacteria** include *Klebsiella pneumoniae*, *Bacteroides fragilis*, certain strains of *Escherichia coli* (such as EPEC and EHEC), among others[1][4]. These organisms can cause gastrointestinal diseases ranging from mild diarrhea to severe inflammatory conditions. However, whether a given bacterium acts as a pathogen depends heavily on host factors such as immune status and microbiome balance. Because this entry refers broadly to many possible organisms rather than one defined molecular target—such as an enzyme, receptor protein, transporter—it is not considered a canonical therapeutic target. Instead, interventions typically aim at modulating overall microbial populations using antibiotics (with risk for collateral damage), probiotics/prebiotics for competitive exclusion/immune modulation, or fecal microbiota transplantation. In summary: "Pathogenic bacterium in gut" is not itself a precise molecular entity but rather describes any member(s) of diverse taxonomic groups capable of causing disease when present in sufficient numbers or under conducive conditions[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacterium in gut.